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A phase II study of induction chemotherapy followed by
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advanced non-small-cell lung cancer
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The optimal management of unresectable locally advanced
non-small-cell lung cancer in older patients has not been
defined to date. The present phase II study was planned to
evaluate the activity and safety of platinum-based induction
chemotherapy followed by concurrent chemoradiotherapy
in elderly patients with locally advanced non-small-cell lung
cancer. Patients received two cycles of paclitaxel
(175mg/m2) and carboplatin (area under the curve: 5) day
1, every 3 weeks. Chemoradiotherapy (thoracic radiation
therapy) was initiated on day 42 and consisted of 1.8Gy
daily, five times per week over 5 weeks (45.0Gy target
dose) followed by 10 2.0Gy daily fractions. Concomitant
chemotherapy was weekly paclitaxel 50mg/mq followed
by weekly carboplatin at an area under the curve of 2. The
eligibility for patients: age 70 or older and histologically
documented untreated non-small-cell lung cancer, locally
advanced, unresectable, stage III A N2 bulky or III B. Thirty
consecutive patients were enrolled onto the study. The
median age was 73 (range 70–76). According to the
intention-to-treat analysis, 1 month after the end of
combined chemoradiotherapy, we observed complete and
partial responses in one and 19 of the 30 patients,
respectively, for an overall response rate of 66% (95%
confidence interval, 45–76%). Median progression-free
survival was 8.7 months (95% confidence interval, 3.4–37.8)
and median survival was 15 months (95% confidence
interval, 4.2–52.1). During the treatment, 12 patients
(40.0%) experienced grade 3–4 neutropenia, two patients
neutropenic fever, and three patients grade 3 anaemia and
grade 3 thrombocytopenia, respectively. Grade 3
oesophagitis, during concomitant radiotherapy, was
observed in six patients (20.0%). No treatment-related
mortality was reported. The investigated sequential
approach including induction chemotherapy followed by
concurrent chemoradiotherapy appears safe and seems a
reasonable chance for the treatment of locally advanced
non-small-cell lung cancer in the elderly population.
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Introduction
Lung cancer is the leading cause of tumour-related
deaths in the elderly population [1]. The majority of
primary lung cancers, approximately 80%, are of non-
small-cell histology. The optimal management of un-
resectable locally advanced non-small-cell lung cancer
(NSCLC) in older patients has not been defined to date.
Reduced organ function, concomitant morbidities, in-
creased medication usage, delayed diagnosis and physi-
cian’s perception constitute barriers to enrolment of
elderly cancer patients in clinical trials [2]. Patients aged
more than 70 years accounted for most of the under-
representation. Excluding all trials of hormonal therapy
for breast cancer, the overall enrolment of patients aged
65, 70 and Z 75 years decreased to 25, 12 and 4%, as
compared with 60, 46 and 31%, respectively, for the
corresponding age group in the US cancer population [3].
It has long been assumed that chemotherapy is too toxic
and of marginal benefit for elderly NSCLC patients and
those with a performance status (PS) of 2. Up to the mid-
1980s, the standard treatment for locally advanced
NSCLC was thoracic radiation therapy (TRT), but the
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results were disappointing, with a median survival time of
less than 1 year and long-term survival rates of 3–7% [4].
Both locally and distant failure were significant problems,
as 70% of patients failed at distant sites and less than 20%
achieved durable local control. In trials comparing
cisplatin-based chemotherapy and radiotherapy to radio-
therapy alone, the combined treatment arm was superior
to radiotherapy alone [5–7]. Furthermore, concurrent
administration of both chemotherapy and radiotherapy
was superior to induction chemotherapy followed by
radiotherapy alone [8–10]. The percentage of patients 70
years old or older in these studies, however, is small,
ranging from 17 to 26% [8–10]. Very few specific
prospective trials on the treatment of locally advanced
NSCLC in the elderly population have been published.
Some phase II studies suggest that low-dose chemother-
apy given together with radiotherapy may be safely
administered to this patient population [11]. The
analysis of retrospective analyses on full-dose sequential
and concurrent chemoradiation is subject to several
methodological and selection biases [11]. Furthermore,
none of these trials evaluated comorbidity as a prognostic
factor [11]. Only specifically designed prospective
studies can value the real role and feasibility of combined
chemoradiotherapy in the treatment of locally advanced
NSCLC in the elderly patients. The present monoin-
stitutional phase II study was planned to evaluate the
activity and toxicity of platinum-based induction che-
motherapy followed by concurrent chemoradiotherapy as
scheduled treatment of elderly patients with locally
advanced unresectable NSCLC.
Patients and methods
Study design, efficacy evaluations and statistical
considerations
The study was a phase II trial. The primary endpoint was
response rate; the secondary endpoints were treatment
toxicity, time to treatment failure and survival obtained
by carboplatin and paclitaxel-based induction chemother-
apy followed by concurrent chemoradiotherapy for the
treatment of locally advanced NSCLC elderly patients.
Tumour response was evaluated by computed tomography
(CT) scan according to standard World Health Organiza-
tion criteria [12] after two cycles of chemotherapy and 1
month after the end of combined chemoradiotherapy
unless suspected early progression of disease. Positron
emission tomography (PET) was also employed for
assessment response of treatment. Survival was recorded
from the day of registration to death or to the date of last
follow-up or the date of point of the study if the patient
was still alive at this time. The overall survival was
estimated using the Kaplan–Meyer technique. The time
to treatment failure was recorded from the day of
registration to the date of first documented progressive
disease (PD) or the date of death regardless of its course
or to the date of point if no PD and no death appeared at
this time. All results presented are based on eligible
patients. According to the intention-to-treat principle, all
patients enrolled were included in the analysis of
treatment administration. The two-stage design proposed
by Simon [13] was used for the study, with the
assumption that a response rate of less than 40% would
not warrant further study and a response rate of 50% or
greater would be considered promising for further study
of this regimen. In the first stage, 10 assessable patients
were entered. If less than four responses were observed,
accrual would stop with the conclusion that the regimen
did not hold promise for further study. If five or more
responses were observed, an additional 20 patients would
be accrued in the second stage of the study.
Patient selection
Patients eligible for enrolment were men or women of the
age 70 years or older and histologically documented
NSCLC, locally advanced, unresectable, stage III A N2
bulky (ipsilateral mediastinal lymph nodes >2 cm in
short-axis diameter at CT) or III B and no previous
surgical resection, chemotherapy or TRT. Mediastino-
scopy or transbronchial needle aspiration was required for
pathologically documented N2 or N3 disease. Histology
could include squamous cell carcinoma, adenocarcinoma
(including bronchoalveolar cell), large-cell anaplastic
carcinoma (including giant and clear-cell carcinomas) or
poorly differentiated NSCLC. Patients with malignant
pleural/pericardial effusion or metastases to controlateral
sopraclavicular lymph nodes or operable stage III B (cT4-
N0–1 for invasion of tracheal carina or multiple nodules in
only one lobe) were excluded. Patients with T4 N0–1
superior sulcus tumours eligible for trimodality therapy
were also excluded. Patients also required having
measurable disease and an Eastern Cooperative Oncology
Group (ECOG) PS 0–1. Adequate haematological,
hepatic and renal function were required. Adequate
pulmonary function with forced expiratory volume
(FEV) in 1 s >900ml and partial oxygen pressure
>50% were mandatory. The evaluation of Cardiovascular
Health Study [14] and the Vulnerable Elderly Survey
[15] score were adopted: only fit (Cardiovascular Health
Study) patients with a Vulnerable Elderly Survey score
<4 were enrolled. The Charlson index was employed as
comorbid illness scale [16]. The overall score is based on
weights, ranging from 1 to 6, which are assigned to 19
selected conditions. Lung cancer was not taken into
account in this calculation. Patients with a Charlson index
score > 1 or 1 for chronic obstructive pulmonary disease
with FEV 1 <50% of the predict value were excluded.
Patients with prior history of malignancy were excluded,
except for carcinoma in situ of the cervix or breast and
nonmelanoma skin cancer. Written informed consent had
to be obtained from all patients.
Treatment plan
For the chemotherapy induction regimen, the patients
received 175mg/m2 of intravenous paclitaxel over 3 h in
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an outpatient setting. Immediately following the pacli-
taxel infusion, the patients received 5 area under the
curve (AUC) of carboplatin, delivered as an intravenous
infusion over 30min. The same regimen of paclitaxel and
carboplatin was repeated 3weeks later on chemother-
apy day 22. The dose of carboplatin was calculated
according to the Calvert formula [17] with glomerular
filtration rate calculated using the Cockroft–Gault
formula [18]. All patients were to receive two treatment
cycles as induction chemotherapy. All chemotherapy
dosing was based on the patient’s actual weight. No dose
escalation was allowed. Standard premedication before
paclitaxel treatment was given consisting of dexametha-
sone 8mg intravenously, chlorpheniramine 10mg intra-
muscular and ranitidine 50mg intravenously. Patients
routinely received antiemetic prophylaxis with a seroto-
nine antagonist. TRT was initiated on day 42 and
consisted of 1.8Gy daily, five times per week over 5
weeks (45.0Gy target dose) followed by 10 2.0Gy daily
fractions (total dose of 65.0Gy in 35 fractions over 7
weeks). The target volume included the post-induction
chemotherapy volume of primary tumour, homolateral
hilar and mediastinal nodes, and 1.5 cm margin. Not
elective nodal irradiations were adopted. Radiotherapy
was delivered with photon beams generated by a linear
accelerator. PET was routinely employed for target
volume and radiotherapy-treatment planning. The thresh-
old dose model for predicting radiation pneumonitis were
employed. The latter relates the volume of lung receiving
more than 20 Gy (V 20) to the risk for developing
radiation pneumonitis with greater risk when V 20 is
superior to 25% [19]. Concurrent chemotherapy was
administered with weekly paclitaxel 50mg/mq as intra-
venous infusion over 1 h followed by weekly carboplatin
at an AUC of 2mg/ml-min administered over 30min.
Dose delay and modifications
Each 21-day chemotherapy cycle could only be started if
the absolute neutrophil count (ANC) and platelet counts
on the day of treatment were at least 1500 and 100 000/
ml, respectively. Treatment was delayed until this level
was achieved. If the delay was greater than 2 weeks, the
patient was taken off the study. If the ANC was <500/ml
or platelet count <50 000/ml at any point during the
cycle, or febrile neutropenia, chemotherapy was adminis-
tered at 75% of the planned dose. Patients came off the
study for grade 3 or 4 neurotoxicity or symptomatic
arrhythmia or atroventricular block. Paclitaxel was admi-
nistered at 50% of the planned dose in the event of
persistent grade 2 neurotoxicity. Two 21-day cycles of
chemotherapy were administered unless PD or intoler-
able toxicity was recorded. During concurrent chemor-
adiotherapy, chemotherapy dose was reduced by 50% if
the granulocyte count dropped from 1000 to 1490/ml or
the platelet count dropped to 75 000 to 99 000/ml.
Whether the granulocyte count dropped to less than
1000/ml or the platelet count dropped to less than 75000/ml,
the chemotherapy administration was omitted. TRT
interruptions were allowed for grade 3–4 oesophagitis/
mucositis, grade 3–4 neutropenia and grade 3–4 throm-
bocytopenia.
Patient evaluation
Pretreatment evaluations included a complete history,
physical examination, complete blood cell count with
differential, serum biochemistry, bronchoscopy, CT scan
of the brain, chest and upper abdomen, radionuclide bone
scan, PET, and electrocardiogram. PET was routinely
employed for staging (patients with clinical N2 or N3 and
negative mediastinum were excluded as patients with
otherwise undetected extrathoracic metastatic disease).
Tumour response was evaluated by CT scan after two
cycles of chemotherapy and 1 month after the end of
combined chemoradiotherapy unless suspected early
progression of disease. PET also was employed for
assessment of tumour response. Before each administra-
tion of chemotherapy, patients underwent a clinical
examination, a routine biochemistry workup and blood
cell counts. Safety parameters were assessed throughout
the induction chemotherapy, chemotherapy/TRT treat-
ment and during the follow-up period until 2 years after
the date of enrolment. During follow-up, TAC and PET
were included every 6 months (every 4 months for the
first year) unless suspect progression of disease. Safety
was assessed through monitoring treatment-emergent
adverse events/toxicities (from induction chemotherapy
and Chemotherapy/TRT treatments), and changes in
clinical laboratory parameters, SpO2, vital signs and
physical examinations. For each patient and each type
of toxicity, the worst degree of toxicity experienced
throughout the treatment was used for the analysis. All
toxicities were coded according to the National Cancer
Institute Common Toxicity Criteria Version 2 [20].
Results
Patient characteristics
From January 2002 to January 2006, 30 consecutive
patients were enrolled onto the study. The median age
was 73 (range 70–76). Forty percent of the patients had
stage III A bulky and 50% had a PS of 0. The distribution
of the Charlson index score was 0 in six patients (20.0%)
and one in 24 patients (80%). Of the patients with
Charlson index score of 1 the distribution of comorbid-
ities was the following: chronic obstructive pulmonary
disease (without FEV 1 <50% of the predict value or
900ml or partial oxygen pressure <50%) in 18 patients,
liver disease in two patients and diabetes in four patients.
The characteristics of the 30 eligible patients are listed in
Table 1.
Treatment administration
Twenty-seven patients received the planned two cycles
of induction chemotherapy. The reason for not complet-
ing induction chemotherapy was patient refusal for
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neutropenic fever (two patients) and diarrhoea (one
patient). During the concurrent chemoradiotherapy, 60%
of patients received all the programmed cycles of
chemotherapy. The reasons for not completing the seven
cycles of concurrent chemotherapy were progressive
decreasing of ECOG PS (two patients) and treatment-
related complications: haematological toxicity (five pa-
tients) and oesophagitis (five patients). The percentage
of patients who completed the planned radiotherapy was
80%. The reasons of failure to complete the planned
radiotherapy were treatment-related complications (oe-
sophagitis) in five patients and poor health in one patient.
No treatment-related deaths were observed.
Haematological toxicity
During the treatment 12 patients (40.0%) experienced
grade 3–4 neutropenia (nine during concomitant treat-
ment, with only two patients developing neutropenic
fever) (Table 2). Three cases of grade 3 anaemia and
three cases of grade 3 thrombocytopenia were observed
during concomitant chemoradiotherapy.
Nonhaematological toxicity
Grade 3 or 4 toxicity was uncommon apart alopecia (Table
2). One patient experienced grade 3 neuropathy. Grade 3
oesophagitis, during concomitant radiotherapy, was ob-
served in six patients (20.0%). During induction treat-
ment, grade 3 nausea/vomiting was reported in four
patients (13.3%) and grade 3 diarrhoea in two patients
(6.6%). No acute radiation pneumonitis or grade 3 or 4
cardiac toxicity was observed.
Response and survival
According to the investigators assessments (Table 3),
1 month after the end of combined chemoradiotherapy,
complete and partial responses were achieved by one and
19 of the 30 patients, respectively, for an overall response
rate of 66.6% [95% confidence interval (CI), 45–76]. In
addition, stable disease (SD) was observed in four
(13.3%) patients and PD in six (20%) patients. The
response assessed with PET was complete and partial in
five and 16 patients, respectively. Furthermore, SD was
observed in three patients and PD in six patients.
Progression was local (one patient) and systemic (five
patients with 2/5 with brain progression). The metabolic
response after induction chemotherapy correlates well
with decrease of tumour size as assessed by standard
criteria, but more patients were judged as complete
responder after chemoradiotherapy by PET (five pa-
tients) than by CT scan (one patient). The objective
response after two cycles of induction chemotherapy was
the following: partial response (PR) and SD were
observed in 19 and five patients, respectively, PD in
three patients. Response was also assessed after one cycle
of induction chemotherapy in three patients (who
refused to completing the planning induction chemother-
apy) and SD were achieved by all patients. Survival
analysis was performed in April 2006, after a median
follow-up of 42 months. The median survival was 15
Table 1 Patient characteristics
Characteristics Number of patients (%)
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Table 2 Safety profile (according to NCI/CTC criteria)
Number of patients with toxicity (%)
Side effects Grade 1 Grade 2 Grade 3 Grade 4 All grades
Haematological
Anaemia 4 (13.3) 3 (10) 3 (10) 0 10 (33.3)
Leucopenia 5 (16.6) 4 (13.3) 15(50) 3 (10) 27 (90.0)
Neutropenia 7 (23.3) 5 (16.6) 9 (30) 3 (10) 24 (80.0)
Thrombocytopenia 5 (16.6) 4 (13.3) 3 (10) 0 12 (40.0)
Nonhaematological
Nausea/vomiting 5 (16.6) 4 (13.3) 4 (13.3) 0 12 (40.0)
Mucositis 3 (10) 4 (13.3) 3 (10) 0 10 (33.3)
Neurotoxicity 5 (16.6) 2 (6.6) 1 (3.3) 0 8 (26.6)
Diarrhoea 4 (13.3) 2 (6.6) 2 (6.6) 0 8 (26.6)
Asthenia 6 (20.0) 4 (13.3) 3 (10) 0 13 (43.3)
Myalgia/arthralgia 4 (13.3) 2 (6.6) 3 (10) 0 9 (30)
Esophagitis 5 (16.6) 5 (16.6) 6 (20) 0 16 (53.3)
NCI/CTC, National Cancer Institute Common Toxicity Criteria.
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months (95% CI, 4.2–52.1). The 3-year survival rate was
20% (95% CI, 11.4–27.6%). Median progression-free
survival was 8.7 months (95% CI, 3.4–37.8). Of the 22
patients who progressed during follow-up, progression
was only local in two patients, locale distant 12 (lung,
liver and bone) and only distant in eight patients (lung,
liver, brain, adrenal glands and bone). The salvage
treatment at progression was gemcitabine (eight pa-
tients), pemetrexed (four patients), weekly paclitaxel
(four patients), gefinitib (four patients) and erlotinib
(two patients).
Discussion
Advancing age is associated with increased incidence of
cancer and an increase in other age-related medical
problems. Lung cancer is now the most common cause of
cancer-related death for elderly population for both men
and women. Approximately 30% of patients with NSCLC
have unresectable locally advanced disease at diagnosis.
The treatment of stage III NSCLC has evolved with
combined-modality therapy, the current standard of care
[7–9,21]. Furthermore, concurrent administration of both
chemotherapy and radiotherapy was superior to induction
chemotherapy followed by radiotherapy alone [8–10] and
immediate combined-modality therapy appeared to have
a greater appeal for treatment of locally advanced
NSCLC [8–10,22,23]. Last, in the randomized phase II
Locally Advanced Multi-Modality Protocol (induction
chemotherapy followed radiotherapy versus induction
chemotherapy followed concurrent chemoradiotherapy
versus immediate concurrent chemoradiotherapy fol-
lowed by consolidation chemotherapy), Belani et al.
showed that concurrent weekly paclitaxel, carboplatin
and radiotherapy followed by consolidation chemotherapy
seems to be associated with the best outcome, but with
greater toxicity [24]. Today, although the optimal
treatment of locally advanced NSCLC has yet to be
defined, immediate concurrent chemoradiotherapy fol-
lowed by consolidation chemotherapy appear the most
efficacious regimen for patients younger than 70 years,
with ECOG PS 0–1 and minimal weight loss. Although
this treatment appears to be associated with the best
outcome, this schedule was associated with greater
toxicity. The question arises whether this is also true
for elderly patients with locally advanced NSCLC.
Multimodality therapy is not frequently offered to those
patients. The percentage of patients 70 years or older in
most of these studies ranges from 17 to 26% [8–10]. It is
important to determine whether elderly patients benefit
from and tolerate combined-modality therapy as much as
their younger counterparts. Lung cancer is a disease of
the elderly and as age increases the probability of
developing comorbid medical illness increases. Particu-
larly, heart-related conditions and chronic obstructive
pulmonary disease were recorded as a current problem as
a part of medical history of the older patients. Underlying
comorbid illness may preclude the safe administration of
aggressive therapy and has independent prognostic
significance for patients with lung cancer. It is necessary
to account for comorbid illness when evaluating age as a
potential prognostic factor. Reports are conflicting
regarding the influence of age on the outcome of patients
and the role of aggressive therapy in NSCLC locally
advanced patients with unfavourable characteristics is
controversial. Hayakawa, evaluating the results of elderly
patients treated with high-dose radiation therapy for
inoperable NSCLC, recommended definitive radiother-
apy without chemotherapy, but a phase II study of the
Southwest Oncology Group suggest, that patients with
poor-risk features can tolerate and derive significant
benefit from aggressive therapy [25,26]. Patients eligible
for the Southwest Oncology Group phase II study had
been excluded from cisplatin-based protocols because of
poor pulmonary or renal function, congestive heart
failure, hearing loss, peripheral neuropathy, or weight
loss. Carboplatin, etoposide and concurrent TRT has
been evaluated. Thirty of the 60 enrolled patients were
between ages 66 and 79. The median overall survival was
13 months. No treatment-related deaths were observed.
The most common grade 3 and 4 toxicities included
leucopenia (50%), thrombocytopenia (23%) and oesopha-
gitis (15%). Indeed, the chemoradiotherapy treatment in
the poor-risk patients yielded a median overall survival
similar to good-risk patients who received cisplatin-based
chemoradiotherapy.
The studies which provided retrospective subgroup
analyses for age as a prognostic factor in patients treated
in radiotherapy/CHT trials could not identify age as a
negative prognostic factor in multivariate analyses [8,27–
29]. Furthermore, in the analysis of the North Central
Cancer Treatment Group trial, survival rates of locally
advanced NSCLC patients treated with concurrent
chemoradiotherapy were equivalent for patients 70 years
or older and younger patients, although patients 70 years
older experienced more grade 4 haematological toxicity
and pneumonitis [30]. Analysis of Radiation Therapy
Oncology Group (RTOG), however, suggest that 70 years
Table 3 Efficacy analysis in elderly advanced NSCLC patients




Complete response 1 (3.3) 20 (66.6)
Partial response 19 (63.3) 26 (86.6)
Stable disease 6 (20)
Disease progression 4 (13.3)
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or older patients achieved the best quality-adjusted
survival with standard radiotherapy alone [31,32].
Similarly, in the phase III Intergroup trial comparing
standard radiotherapy, standard radiotherapy with con-
comitant cisplatin and vinblastine and hyper-fractionated
radiotherapy, for patients over age 70 years (66 of 490
enrolled patients), median survival on the radiotherapy
arm (13.1 months) exceeded median survival in the
concurrent chemoradiotherapy arm (10.9 months) [6].
Moreover, the RTOG 94-10 study showed that elderly
patients had the best median survival with concurrent
therapy [33]. The RTOG 94-10 compared sequential
therapy with concurrent chemoradiotherapy and concur-
rent chemotherapy/hyper-fractionated radiotherapy. Elig-
ibility was restricted to good-risk patients. Of the 610
patients enrolled, 104 were age 70 or older. Median
survival in the elderly favoured concurrent chemother-
apy-standard radiotherapy arm (22.4 versus 16.4 and 10.8
months in the sequential and concurrent chemotherapy/
hyper-fractionated radiotherapy arm, respectively). The
rate of grade 3–4 neutropenia and grade >3 oesophagitis
was higher in older patients. Moreover, in the analysis by
Rocha-Lima of the CALGB 9130 trial, the outcome was
equivalent for patients 70 years or older and younger
counterparts [34]. Last, in a recent meta-analysis of
concurrent modality therapy based on platinum com-
pounds, concomitant chemoradiotherapy appeared to
have a differential effect on survival according to age,
with the greater benefit for older patients [35]. In
summary, there is conflicting data regarding the utility of
aggressive combined-modality treatment in elderly pa-
tients with advanced NSCLC. Survival benefit can be
achieved, but at the expense of increase in toxicity. These
studies suggest that appropriately selected fit patients
should be treated similarly to fit young patients. Older
patients had similar local control and survival as younger
patients, but experienced more myelosuppression and
non-haematological toxicity (more pneumonitis on the
North Central Cancer Treatment Group trial, more
oesophagitis in the RTOG 9410 trial and more renal
complications in the CALGB 9130 trial). There is a need
to conduct phase III trials in locally advanced NSCLC
specifically targeting the elderly, but, until such studies
are conducted, elderly locally advanced NSCLC patients
with good PS and limited comorbidity may be treated
with concurrent chemoradiotherapy. The present phase
II study was to assess the antitumour activity and toxicity
of platinum-based induction chemotherapy followed by
concurrent chemoradiotherapy as treatment of locally
advanced, unresectable, stage III A N2 bulky or III B
NSCLC in elderly patients, with good functional status
and low comorbidity index. We used paclitaxel and
carboplatin for the proved efficacy in the treatment of
NSCLC, and omitted cisplatin for the age of patients and
the better integration with radiation therapy of carbopla-
tin. No treatment-related mortality was reported. The
observed 20% of grade 3 oesophagitis in this study is
similar to that reported in the literature (15–20%)
[36,37]. No grade 3/4 lung toxicity was reported. The
apparently high incidence of reported severe neutropenia
(40%) could be related to the high frequency (weekly) of
blood count determination performed in the present trial
during the concomitant radiochemotherapy phase. In this
study, the combined-modality therapy appeared feasible
for elderly patients with good PS and limited comorbid
conditions.
During this study, an overall response of 66% and a median
survival of 15 months were reported. These activity data
are congruent with those reported by most studies of
combined chemoradiotherapy in patients with locally
advanced NSCLC younger than 70 years. The addiction
of induction chemotherapy resulted in no survival
advantage [23], but induction chemotherapy permitted
that the TRT target was the postinduction tumour
volume. As the impact of acute toxicity may be greater
for elderly patients, limited field radiation, as in this
trial, should be considered. Toxicity to the lungs and
oesophagus can be decreased by limited irradiation
without a negative impact on clinical activity. In conclu-
sion, this study investigated the sequential approach
including induction chemotherapy followed by concurrent
chemoradiotherapy. This approach merits further evalua-
tion in large phase III studies specifically designed for the
elderly population with locally advanced NSCLC.
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